Ampio Pharmaceuticals (AMPE) AI Stock Analysis

• Market Cap: $3.06K
• Dividend Yield: N/A
• Average Volume (3M): 490.00
• Price to Earnings (P/E): ―
• Beta (1Y): -3.98
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -11.09
• Shares Outstanding: 1,135,358
• 10 Day Avg. Volume: 984
• 30 Day Avg. Volume: 490
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 27 Underperform
• Price Target: ―

Ampio Pharmaceuticals faces significant financial challenges with zero revenues and ongoing losses. The absence of technical indicators, poor valuation metrics, and lack of earnings call insights further contribute to a low overall stock score.

Ampio Pharmaceuticals Business Overview & Revenue Model

Company Description

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

How the Company Makes Money

Ampio Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company's earnings are largely dependent on the successful clinical development, regulatory approval, and subsequent market entry of its lead product, Ampion. Revenue streams may include licensing agreements, partnerships with other pharmaceutical companies, or eventual product sales if Ampion receives approval. As a development-stage company, Ampio also relies on funding from investors, grants, or collaborations to support its research and development activities and operational expenses. Significant partnerships or collaborations could enhance its financial standing and facilitate access to broader markets.

Ampio Pharmaceuticals Financial Statement Overview

Summary

Ampio Pharmaceuticals exhibits severe financial difficulties with zero revenue, ongoing losses, declining equity, and negative cash flow, indicating critical financial distress.

Income Statement

Ampio Pharmaceuticals has consistently reported zero revenue over the last five years, indicating a lack of income generation. The company has faced significant operating losses, as reflected by negative EBIT and net income figures, leading to negative profit margins. This suggests ongoing financial struggles with profitability.

Balance Sheet

The balance sheet shows a decreasing trend in stockholders' equity and total assets over the years, which could indicate financial instability. The debt-to-equity ratio is relatively low, suggesting low leverage, but the decreasing equity raises concerns. The company has maintained a positive equity ratio, indicating some level of asset stability despite financial challenges.

Cash Flow

Ampio Pharmaceuticals has experienced negative operating and free cash flows, indicating insufficient cash generation from operations. This trend has persisted over the years, with no significant improvement in cash flow metrics. The lack of positive cash flow poses a risk to the company's ability to finance its operations and potential growth.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-250.00K	-2.08M	-1.09M	-1.18M	-1.27M
EBITDA	0.00	-23.16M	-22.97M	-14.59M	-17.30M
Net Income	-8.63M	-16.34M	-17.07M	-15.89M	-13.63M
Balance Sheet
Total Assets	5.74M	13.59M	38.83M	22.88M	14.00M
Cash, Cash Equivalents and Short-Term Investments	4.09M	12.65M	33.89M	17.35M	6.53M
Total Debt	274.00K	614.00K	925.00K	1.21M	1.47M
Total Liabilities	2.38M	1.80M	11.54M	5.37M	7.56M
Stockholders Equity	3.36M	11.79M	27.28M	17.51M	6.44M
Cash Flow
Free Cash Flow	-8.56M	-21.13M	-14.19M	-14.79M	-15.40M
Operating Cash Flow	-8.56M	-21.13M	-14.09M	-14.73M	-15.38M
Investing Cash Flow	0.00	0.00	-97.00K	-63.00K	-22.00K
Financing Cash Flow	0.00	-111.00	30.73M	25.61M	14.35K

Ampio Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
GRI	45 Neutral	$3.55M	―	-248.95%	―	―	98.45%
ONCO	33 Underperform	$4.78M	―	-254.09%	―	-9.34%	93.84%
SLRX	30 Underperform	$2.94M	―	-660.37%	―	―	74.27%
PCSA	29 Underperform	$11.26M	―	-212.38%	―	―	57.99%
AMPE	27 Underperform	$3.06K	―	-256.90%	―	―	―
QNRX	25 Underperform	$4.34M	―	-244.31%	―	―	-146.64%